Enhanced growth inhibition by combined DNA methylation/HDAC inhibitors in lung tumor cells with silenced CDKN2A

International Journal of Oncology

Volumn 37, Issue 4, 2010, Pages 963-971

  Chen, Min ^a,c   Voeller, Donna ^c   Marquez, Victor E ^c   Kaye, Frederic J ^a,c   Steeg, Patricia S ^c   Giaccone, Giuseppe ^c   Zajac Kaye, Maria ^a,b,c  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

CDKN2A; Depsipeptide; DNA methylation; HDAC inhibition; Lung cancer; Zebularine

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; DEPSIPEPTIDE; DNA; MESSENGER RNA; PROTEIN P16; ZEBULARINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DNA METHYLATION; DRUG EFFECT; DRUG POTENTIATION; GENE; GENE DELETION; GENE EXPRESSION; GENE LOCUS; GENE SILENCING; GROWTH INHIBITION; HUMAN; HUMAN CELL; LUNG CANCER; LUNG TUMOR; PRIORITY JOURNAL; TUMOR GROWTH;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CPG ISLANDS; CYTIDINE; DEPSIPEPTIDES; DNA METHYLATION; DNA MODIFICATION METHYLASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENZYME INHIBITORS; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, P16; HISTONE DEACETYLASE INHIBITORS; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; TIME FACTORS;

EID: 77956530122     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000747     Document Type: Article

References (47)

1. Baylin SB: DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2 (Suppl. 1): S4-S11, 2005. (Pubitemid 43135229)
2. Jones PA and Baylin SB: The epigenomics of cancer. Cell 128: 683-692, 2007.
3. Otterson GA, Khleif SN, Chen W, Coxon AB and Kaye FJ: CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16INK4 protein induction by 5-aza 2′deoxycytidine. Oncogene 11: 1211-1216, 1995.
4. Yoo CB and Jones PA: Epigenetic therapy of cancer: Past, present and future. Nat Rev Drug Discov 5: 37-50, 2006.
5. Momparler RL and Derse D: Kinetics of phosphorylation of 5-aza-2′-deoxycytidine by deoxycytidine kinase. Biochem Pharmacol 28: 1443-1444, 1979.
6. Juttermann R, Li E and Jaenisch R: Toxicity of 5-aza-2′- deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci USA 91: 11797-11801, 1994.
7. Santi DV, Norment A and Garrett CE: Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc Natl Acad Sci USA 81: 6993-6997, 1984.
8. Graff JR, Gabrielson E, Fujii H, Baylin SB and Herman JG: Methylation patterns of the E-cadherin 5′ CPG island are unstable and reflect the dynamic, heterogeneous loss of Ecadherin expression during metastatic progression. J Biol Chem 275: 2727-2732, 2000. (Pubitemid 30082043)
9. Herman JG, Umar A, Polyak K, et al: Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 95: 6870-6875, 1998.
10. Kawano S, Miller CW, Gombart AF, et al: Loss of p73 gene expression in leukemias/lymphomas due to hypermethylation. Blood 94: 1113-1120, 1999.
11. Wong IH, Ng MH, Huang DP and Lee JC: Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: Potential prognostic implications. Blood 95: 1942-1949, 2000.
12. Herman JG, Latif F, Weng Y, et al: Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 91: 9700-9704, 1994. (Pubitemid 24311875)
13. Issa JP, Garcia-Manero G, Giles FJ, et al: Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′- deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103: 1635-1640, 2004.
14. Momparler RL and Ayoub J: Potential of 5-aza-2′-deoxycytidine (decitabine) a potent inhibitor of DNA methylation for therapy of advanced non-small cell lung cancer. Lung Cancer 34 (Suppl. 4): S111-S115, 2001.
15. Momparler RL, Rivard GE and Gyger M: Clinical trial on 5-aza-2′-deoxycytidine in patients with acute leukemia. Pharmacol Ther 30: 277-286, 1985.
16. Schrump DS, Fischette MR, Nguyen DM, et al: Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res 12: 5777-5785, 2006.
17. Laliberte J, Marquez VE and Momparler RL: Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2′-deoxycytidine by human cytidine deaminase. Cancer Chemother Pharmacol 30: 7-11, 1992.
18. Stresemann C and Lyko F: Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer 123: 8-13, 2008. (Pubitemid 351705186)
19. Kim CH, Marquez VE, Mao DT, Haines DR and McCormack JJ: Synthesis of pyrimidin-2-one nucleosides as acid-stable inhibitors of cytidine deaminase. J Med Chem 29: 1374-1380, 1986.
20. Hurd PJ, Whitmarsh AJ, Baldwin GS, et al: Mechanism-based inhibition of C5-cytosine DNA methyltransferases by 2-h pyrimidinone. J Mol Biol 286: 389-401, 1999.
21. Cheng JC, Weisenberger DJ, Gonzales FA, et al: Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol Cell Biol 24: 1270-1278, 2004.
22. Marquez VE, Kelley JA, Agbaria R, et al: Zebularine: A unique molecule for an epigenetically based strategy in cancer chemotherapy. Ann NY Acad Sci 1058: 246-254, 2005.
23. Cheng JC, Matsen CB, Gonzales FA, et al: Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst 95: 399-409, 2003.
24. Cheng JC, Yoo CB, Weisenberger DJ, et al: Preferential response of cancer cells to zebularine. Cancer Cell 6: 151-158, 2004.
25. Cameron EE, Bachman KE, Myohanen S, Herman JG and Baylin SB: Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21: 103-107, 1999.
26. Primeau M, Gagnon J and Momparler RL: Synergistic antineoplastic action of DNA methylation inhibitor 5-aza-2′-deoxycytidine and histone deacetylase inhibitor depsipeptide on human breast carcinoma cells. Int J Cancer 103: 177-184, 2003.
27. Wu LP, Wang X, Li L, et al: Histone deacetylase inhibitor depsipeptide activates silenced genes through decreasing both CPG and H3K9 methylation on the promoter. Mol Cell Biol 28: 3219-3235, 2008.
28. Sandor V, Senderowicz A, Mertins S, et al: P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br J Cancer 83: 817-825, 2000.
29. Bates SE and Piekarz RL: Histone deacetylase inhibitors in combinations: Will the preclinical promises be kept? Cancer J 13: 80-83, 2007.
30. Zhu WG, Lakshmanan RR, Beal MD and Otterson GA: DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res 61: 1327-1333, 2001. (Pubitemid 34292551)
31. Yu XD, Wang SY, Chen GA, et al: Apoptosis induced by depsipeptide FK228 coincides with inhibition of survival signaling in lung cancer cells. Cancer J 13: 105-113, 2007.
32. Zhao Y, Tan J, Zhuang L, Jiang X, Liu ET and Yu Q: Inhibitors of histone deacetylases target the RB-E2F1 pathway for apoptosis induction through activation of proapoptotic protein bim. Proc Natl Acad Sci USA 102: 16090-16095, 2005.
33. Zhu WG, Dai Z, Ding H, et al: Increased expression of unmethylated CDKN2D by 5-aza-2′-deoxycytidine in human lung cancer cells. Oncogene 20: 7787-7796, 2001.
34. Klimek VM, Fircanis S, Maslak P, et al: Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clin Cancer Res 14: 826-832, 2008.
35. Sandor V, Bakke S, Robey RW, et al: Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 8: 718-728, 2002.
36. Rahman L, Voeller D, Rahman M, et al: Thymidylate synthase as an oncogene: A novel role for an essential DNA synthesis enzyme. Cancer Cell 5: 341-351, 2004. (Pubitemid 38482070)
37. Alexandrova N, Niklinski J, Bliskovsky V, et al: The N-terminal domain of c-Myc associates with alpha-tubulin and microtubules in vivo and in vitro. Mol Cell Biol 15: 5188-5195, 1995.
38. Niklinski J, Claassen G, Meyers C, et al: Disruption of Myc-tubulin interaction by hyperphosphorylation of c-Myc during mitosis or by constitutive hyperphosphorylation of mutant c-Myc in Burkitt's lymphoma. Mol Cell Biol 20: 5276-5284, 2000.
39. Chou TC and Talalay P: Analysis of combined drug effects - a new look at a very old problem. Trends Pharmacol Sci 4: 450-454, 1983.
40. Chou TC and Talaly P: A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems. J Biol Chem 252: 6438-6442, 1977.
41. Otterson GA, Kratzke RA, Coxon A, Kim YW and Kaye FJ: Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wild-type RB. Oncogene 9: 3375-3378, 1994.
42. Yu X, Guo ZS, Marcu MG, et al: Modulation of p53, Erbb1, Erbb2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst 94: 504-513, 2002. (Pubitemid 34411289)
43. Steiner FA, Hong JA, Fischette MR, et al: Sequential 5-aza 2′-deoxycytidine/depsipeptide FK228 treatment induces tissue factor pathway inhibitor 2 (TFPI-2) expression in cancer cells. Oncogene 24: 2386-2397, 2005.
44. Herranz M, Martin-Caballero J, Fraga MF, et al: The novel DNA methylation inhibitor zebularine is effective against the development of murine T-cell lymphoma. Blood 107: 1174-1177, 2006.
45. Scott SA, Lakshimikuttysamma A, Sheridan DP, Sanche SE, Geyer CR and DeCoteau JF: Zebularine inhibits human acute myeloid leukemia cell growth in vitro in association with p15INK4B demethylation and reexpression. Exp Hematol 35: 263-273, 2007.
46. Holleran JL, Parise RA, Joseph E, et al: Plasma pharmacokinetics, oral bioavailability, and interspecies scaling of the DNA methyltransferase inhibitor, zebularine. Clin Cancer Res 11: 3862-3868, 2005.
47. Yoo CB, Chuang JC, Byun HM, et al: Long-term epigenetic therapy with oral zebularine has minimal side-effects and prevents intestinal tumors in mice. Cancer Prev Res 1: 233-240, 2008.